Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$190.27 ▲ +1.55
(+0.82%)
MKT CAP: $40.78B • VOL: 1.32M
52W L $57 52W H $224
RVMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $11.6M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $5.1M |
| Gross Margin % | — | — | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$1.18B | -$689.5M | -$487.2M |
| Operating Margin % | — | — | -4207.1% |
| Net Income (GAAP) | -$1.13B | -$600.0M | -$436.0M |
| EBITDA (Normalized) | -$1.17B | -$681.3M | -$486.8M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$897.7M | -$557.4M | -$350.6M |
| Capital Expenditures (CapEx) | $16.0M | $10.3M | $521.1K |
| Free Cash Flow (FCF) | -$913.7M | -$567.7M | -$351.1M |
| FCF Margin % | — | — | -3031.9% |
| Return on Invested Capital (ROIC %) | -45.0% | -29.4% | -2.8% |
| Cash & Short-Term Equivalents | $383.7M | $543.1M | $2.47B |
| Total Debt (Short + Long Term) | $325.4M | $131.9M | $5.25B |
| Total Stockholders' Equity | $1.63B | $2.27B | $10.77B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RVMD.